Stock TRIB TRINITY BIOTECH PLC
Add to a list
To use this feature you must be a member
Log inSign up

Financials Trinity Biotech plc

Equities

TRIB

US8964385046

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
1.83 USD 0.00% Intraday chart for Trinity Biotech plc +1.36% -14.69%
Apr. 25 European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Thursday Trading MT
Apr. 23 European Equities Traded in the US as American Depositary Receipts Jump in Tuesday Trading MT

Valuation

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Capitalization 1 117.8 47.93 21.6 79.64 29.89 37.73
Enterprise Value (EV) 1 154.1 99.99 107.4 156.6 103.2 103.3
P/E ratio -2.74 x -2.17 x -0.74 x -12.5 x 38.2 x -0.81 x
Yield - - - - - -
Capitalization / Revenue 1.19 x 0.49 x 0.24 x 0.78 x 0.32 x 0.5 x
EV / Revenue 1.55 x 1.03 x 1.19 x 1.54 x 1.11 x 1.38 x
EV / EBITDA 17.2 x 10.8 x 27.6 x 7.62 x 9.78 x -10.9 x
EV / FCF -13.9 x -6.95 x -14.2 x 25 x -133 x -12.2 x
FCF Yield -7.2% -14.4% -7.03% 4.01% -0.75% -8.2%
Price to Book 1.64 x 1.09 x 4.58 x -35.9 x -93.7 x -17.3 x
Nbr of stocks (in thousands) 4,621 4,186 4,180 4,180 4,180 7,622
Reference price 2 25.50 11.45 5.167 19.05 7.150 4.950
Announcement Date 4/20/18 5/14/19 6/15/20 4/30/21 5/2/22 5/16/23
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Net sales 1 99.14 97.04 90.44 102 92.96 74.78
EBITDA 1 8.969 9.262 3.895 20.56 10.55 -9.521
EBIT 1 5.478 6.705 0.183 18.45 8.901 -10.92
Operating Margin 5.53% 6.91% 0.2% 18.09% 9.57% -14.6%
Earnings before Tax (EBT) 1 -39.88 -23.18 -30 -6.633 0.751 -41.19
Net income 1 -40.27 -22.09 -28.91 -6.388 0.875 -41.01
Net margin -40.62% -22.76% -31.97% -6.26% 0.94% -54.84%
EPS 2 -9.312 -5.284 -6.982 -1.528 0.1871 -6.078
Free Cash Flow 1 -11.09 -14.38 -7.552 6.274 -0.7735 -8.473
FCF margin -11.19% -14.82% -8.35% 6.15% -0.83% -11.33%
FCF Conversion (EBITDA) - - - 30.51% - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 4/20/18 5/14/19 6/15/20 4/30/21 5/2/22 5/16/23
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2020 Q3 2020 Q4 2021 Q1 2021 Q2 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2
Net sales 1 32.01 32.76 25.59 25.84 22 19.52 18.78 - 19.5 18.04 14.83 13.5
EBITDA - - - - - - - - - - - -
EBIT 1 9.085 9.066 3.078 6.286 2.748 1.687 0.173 - -0.098 -7.809 -3.919 -2.183
Operating Margin 28.38% 27.67% 12.03% 24.32% 12.49% 8.64% 0.92% - -0.5% -43.3% -26.43% -16.17%
Earnings before Tax (EBT) 1 7.712 -10.75 1.707 - 1.581 -2.45 -12.43 - -8.941 -10.09 -6.316 -3.373
Net income 1 7.325 -10.02 1.602 -0.783 1.321 -1.264 -12.28 -9.706 -8.945 -10.08 -5.809 -3.272
Net margin 22.88% -30.59% 6.26% -3.03% 6% -6.47% -65.4% - -45.87% -55.89% -39.17% -24.24%
EPS 2 1.750 -2.400 0.3850 -0.1850 0.3150 -0.3000 -2.500 -1.430 -1.175 -1.325 -0.7600 -0.4500
Dividend per Share - - - - - - - - - - - -
Announcement Date 11/17/20 3/25/21 5/25/21 9/9/21 12/15/21 4/11/22 6/30/22 11/3/22 12/15/22 3/23/23 7/6/23 -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Net Debt 1 36.2 52.1 85.8 77 73.3 65.6
Net Cash position 1 - - - - - -
Leverage (Debt/EBITDA) 4.04 x 5.622 x 22.02 x 3.745 x 6.946 x -6.892 x
Free Cash Flow 1 -11.1 -14.4 -7.55 6.27 -0.77 -8.47
ROE (net income / shareholders' equity) -44.5% -41.5% -119% -482% -73.2% 3,287%
ROA (Net income/ Total Assets) 1.55% 2.43% 0.08% 8.82% 4.46% -6.47%
Assets 1 -2,603 -908.3 -35,740 -72.44 19.61 633.9
Book Value Per Share 2 15.60 10.50 1.130 -0.5300 -0.0800 -0.2900
Cash Flow per Share 2 5.630 7.240 3.640 6.540 6.200 0.8600
Capex 1 4.84 7.53 2.14 3.21 1.81 1.1
Capex / Sales 4.88% 7.76% 2.36% 3.15% 1.95% 1.47%
Announcement Date 4/20/18 5/14/19 6/15/20 4/30/21 5/2/22 5/16/23
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Quarterly earnings - Rate of surprise

Company calendar

Sector Diagnostic & Testing Substances

1st Jan change Capi.
TRINITY BIOTECH PLC Stock Trinity Biotech plc
-14.69% 17.28M
BIOMÉRIEUX Stock bioMérieux
+0.89% 12.8B
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD. Stock Shenzhen New Industries Biomedical Engineering Co., Ltd.
-10.29% 7.61B
DIASORIN S.P.A. Stock DiaSorin S.p.A.
+1.78% 5.41B
AUTOBIO DIAGNOSTICS CO., LTD. Stock Autobio Diagnostics Co., Ltd.
-1.16% 4.51B
LANTHEUS HOLDINGS, INC. Stock Lantheus Holdings, Inc.
+5.74% 4.49B
10X GENOMICS, INC. Stock 10x Genomics, Inc.
-50.70% 3.29B
ANDON HEALTH CO., LTD. Stock Andon Health Co., Ltd.
+12.21% 2.73B
VITROLIFE AB Stock Vitrolife AB
-16.13% 2.02B
GUANGZHOU WONDFO BIOTECH CO.,LTD Stock Guangzhou Wondfo Biotech Co.,Ltd
-11.50% 1.73B
Diagnostic & Testing Substances
  1. Stock Market
  2. Equities
  3. TRIB Stock
  4. Financials Trinity Biotech plc